Emergent BioSolutions Inc. (EBS): Total Liabilities
$796.00M
As of 2025-12-31
$775.40M
As of 2026-06-30
-23.5%
3-year compound annual growth
-11.1%
5-year compound annual growth
+7.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $796.00M | -12.2% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $906.90M | -22.7% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $1.17B | -34.0% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $1.78B | +32.1% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $1.35B | -6.3% | 2023-12-11, Balance as of period end |
| 2020-12-31 | $1.44B | +15.9% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $1.24B | +1.7% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $1.22B | +671.7% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $157.90M | -57.8% | 2019-02-22, Balance as of period end |
| 2016-12-31 | $373.91M | -0.9% | 2018-02-23, Balance as of period end |
| 2015-12-31 | $377.47M | n/c | 2017-02-28, Balance as of period end |
| 2014-12-31 | $385.49M | n/c | 2016-02-29, Balance as of period end |
| 2013-12-31 | $137.47M | +12.6% | 2015-03-09, Balance as of period end |
| 2012-12-31 | $122.10M | -6.2% | 2014-03-10, Balance as of period end |
| 2011-12-31 | $130.14M | +2.7% | 2013-03-08, Balance as of period end |
| 2010-12-31 | $126.76M | n/a | 2012-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
Compare EBS, PCRX, CORT, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗